Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a high fatality rate. Currently, chemotherapy is the major treatment option, but the clinical result is unsatisfactory. A research team led ...
Apr 15, 2021
0
11
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
Apr 6, 2021
0
111
ProAgio, a drug developed by Georgia State University biology professor Zhi-Ren Liu and his team, is effective at treating pancreatic cancer and prolonging survival in mice, according to a study published in the journal Cellular ...
Feb 9, 2021
0
1
A new study led by the University of Westminster shows that removing small genetic parts of our genomes called microRNAs from triple negative breast cancer cells can reverse its spread.
Feb 5, 2021
0
225
Using the developing eye of the fruit fly as a test platform, researchers found that RPS-12 protein overproduction appears to trigger triple-negative breast cancer and possibly some other malignancies. The protein indirectly ...
Jan 29, 2021
0
3
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how breast cancer cells hide from immune cells to stay alive. The discovery could lead to better immunotherapy treatment ...
Jan 27, 2021
0
37
Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, ...
Dec 10, 2020
0
1
Patients with cancer have multiple treatment options available to them today, but each has its drawbacks. Chemotherapy kills rapidly dividing cancer cells, but it also damages healthy cells in the body and often does not ...
Nov 10, 2020
0
131
Adding an immunotherapy agent to a three-drug chemotherapy regimen can improve the likelihood that early-stage triple-negative breast cancer will recede to undetectable levels, data from a clinical trial led by Dana-Farber/Brigham ...
Sep 21, 2020
0
4
US pharmaceutical giant Gilead Sciences confirmed Sunday that it is buying American biotech firm Immunomedics, which makes a breast cancer drug, for $21 billion.
Sep 14, 2020
0
2
